Protagonist Therapeutics (NASDAQ:PTGX) Upgraded at BidaskClub

Share on StockTwits

Protagonist Therapeutics (NASDAQ:PTGX) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Saturday, BidAskClub reports.

Other analysts also recently issued reports about the stock. Zacks Investment Research downgraded shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. ValuEngine raised shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, December 10th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $18.90.

Shares of PTGX stock opened at $9.06 on Friday. The company has a market capitalization of $250.84 million, a price-to-earnings ratio of -3.08 and a beta of 1.38. Protagonist Therapeutics has a one year low of $4.47 and a one year high of $16.67. The company’s fifty day moving average price is $7.65 and its 200-day moving average price is $10.09. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.68 and a quick ratio of 4.68.

In related news, Director Bryan Giraudo purchased 8,000 shares of the company’s stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average cost of $5.70 per share, for a total transaction of $45,600.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at $57,000. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Suneel Gupta purchased 30,000 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were bought at an average price of $5.13 per share, with a total value of $153,900.00. Following the completion of the transaction, the executive vice president now owns 389,824 shares of the company’s stock, valued at $1,999,797.12. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 39,175 shares of company stock worth $205,493. Insiders own 14.20% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of PTGX. Meeder Asset Management Inc. lifted its position in shares of Protagonist Therapeutics by 1,433.3% during the 3rd quarter. Meeder Asset Management Inc. now owns 3,450 shares of the company’s stock worth $41,000 after buying an additional 3,225 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Protagonist Therapeutics by 20.7% during the 3rd quarter. Rhumbline Advisers now owns 15,540 shares of the company’s stock worth $187,000 after purchasing an additional 2,662 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Protagonist Therapeutics during the 3rd quarter worth $926,000. State Street Corp boosted its position in shares of Protagonist Therapeutics by 19.9% during the 3rd quarter. State Street Corp now owns 315,043 shares of the company’s stock worth $3,784,000 after purchasing an additional 52,333 shares in the last quarter. Finally, California State Teachers Retirement System boosted its position in shares of Protagonist Therapeutics by 13.7% during the 3rd quarter. California State Teachers Retirement System now owns 26,542 shares of the company’s stock worth $319,000 after purchasing an additional 3,195 shares in the last quarter. 79.84% of the stock is owned by institutional investors and hedge funds.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.

Featured Article: volatile stocks

Analyst Recommendations for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Victory Capital Management Inc. Buys 743 Shares of Cable One Inc
Victory Capital Management Inc. Buys 743 Shares of Cable One Inc
Victory Capital Management Inc. Buys 22,273 Shares of Mid-America Apartment Communities Inc
Victory Capital Management Inc. Buys 22,273 Shares of Mid-America Apartment Communities Inc
Victory Capital Management Inc. Boosts Holdings in Aon PLC
Victory Capital Management Inc. Boosts Holdings in Aon PLC
Victory Capital Management Inc. Boosts Stock Position in iShares Russell 3000 ETF
Victory Capital Management Inc. Boosts Stock Position in iShares Russell 3000 ETF
Victory Capital Management Inc. Has $8.58 Million Stake in Advance Auto Parts, Inc.
Victory Capital Management Inc. Has $8.58 Million Stake in Advance Auto Parts, Inc.
Victory Capital Management Inc. Has $8.45 Million Stake in Dell Inc.
Victory Capital Management Inc. Has $8.45 Million Stake in Dell Inc.


 
© 2006-2020 Zolmax.